Dataset opportunity
Artoptical — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Artoptical, usable for Diagnostic AI and Computer Vision.
Score
64.9
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in ophthalmology market = $209.23M in 2024, CAGR 36.79% (2025-2030) (source: Grand View Research). [1]
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-16
J&J commits $1B to expand contact lens production in Florida
manufacturingdive.com ↗ - 📰press2026-06-16
J&J commits $1B to expand contact lens production in Florida
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Artoptical possesses a specialized Medical Imaging Dataset composed of a large image_collection of corneal scans and associated `medical_records`, including patient prescriptions. This collection is uniquely suited for developing and validating high-precision Diagnostic AI models, as it directly links ocular topography to specific patient data, providing a comprehensive basis for training algorithms in ophthalmic disease detection.
The business value is grounded in the rapidly expanding AI in ophthalmology market, estimated at $209.23 million in 2024 and projected to grow at a CAGR of 36.79%. [1] While access is subject to negotiation due to sensitive health information (HIPAA/GDPR), shared data ownership, and linked proprietary lens design parameters, this complexity also underlines the dataset's rare and high-value nature. This unique combination of data is critical for buyers seeking to build a competitive advantage in a booming market. ⚠ Diligence (valuable data, access to negotiate): Contains sensitive health information (HIPAA/GDPR) including corneal scans and patient prescriptions.; Data ownership may be shared with the prescribing eye care practitioners.; Proprietary lens design parameters are linked to specific ocular topographies. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Evidence confirms Artoptical possesses a proprietary collection of secure images, including patient scans and topographies, directly linked to optical product orders. This dataset is a prime asset for developing and validating diagnostic AI models, a critical need for companies targeting the rapidly expanding AI in ophthalmology market. With the market projected to grow at a CAGR of 36.79%, the ability to link imaging data to specific prescription outcomes offers a unique ground truth for training next-generation algorithms.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand for AI-ready ophthalmic data is exceptionally high, driven by the market's explosive growth forecast with a 36.79% CAGR. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 2 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — Art Optical is an ideal target as it's an independent SME manufacturer of custom contact lenses whose core business is not selling data, but which necessarily accumulates valuable proprietary data on lens design, fitting, and patient parameters as a by-product of its operations.
- Deep Qualification90
✓ pass — Art Optical is a data holder, not a seller, possessing a coherent and highly sensitive medical imaging dataset as a byproduct of its custom contact lens manufacturing; data ownership is likely mixed with practitioners, and a new data-reception portal was launched in March 2025.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Image collection
The company manages a portal for healthcare providers to upload secure images, including patient scans and topographies, creating a valuable, proprietary repository for training computer vision models.
Medical records / imaging
The dataset includes longitudinal order history and patient statements, providing crucial metadata that links imaging data to specific lens orders and corrective outcomes.
Industrial data
The data captures detailed prescription parameters for customizable lenses over time, offering structured data on base curve, diameter, and power that can be correlated with patient imagery.
Coverage
Scanned sources
Deliverable
Premium dataset report
Artoptical Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in ophthalmology market = $209.23M in 2024, CAGR 36.79% (2025-2030) (source: Grand View Research). [1]. Investment score 64.9/100 (confidence 0.49). Recommended action: Data Sharing Agreement.